2020
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, Mansukhani MM, Murty VV, Hsiao S, Alobeid B, Bhagat G. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica 2020, 107: 201-210. PMID: 33297669, PMCID: PMC8719101, DOI: 10.3324/haematol.2020.267294.Peer-Reviewed Original ResearchConceptsPlasmablastic lymphomaJAK/STATSolid organ allograft recipientsTargetable oncogenic pathwaysOrgan allograft recipientsAllograft recipientsComprehensive histopathologicEBV infectionHIV infectionPlasmablastic myelomaClinical outcomesClinicopathologic featuresYears postdiagnosisAggressive neoplasmDisease subsetsEBV- casesImmunophenotypic heterogeneityImmunophenotypic evaluationMAP kinaseImmunocompromised individualsMYC rearrangementDisease pathogenesisPhenotypic spectrumNotch pathway genesOncogenic pathways
2006
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.Peer-Reviewed Original ResearchConceptsFollicular Lymphoma International Prognostic IndexOverall survivalClinical featuresPrimary nodal marginal zone B-cell lymphomaHepatitis C virus serologyMarginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaC virus serologyStage IV diseaseWorse overall survivalInternational Prognostic IndexB-cell lymphomaWorse OSPrognostic indexVirus serologyPrognostic assessmentRare diseaseMultivariate analysisLactate dehydrogenaseDiseasePatientsPrognosisLymphomaSerology
2004
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma
Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplantation 2004, 34: 175-179. PMID: 15170171, DOI: 10.1038/sj.bmt.1704551.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsB-LymphocytesBone Marrow PurgingCytarabineFemaleHematopoietic Stem Cell MobilizationHumansImmunophenotypingLymphoma, FollicularLymphoma, Mantle-CellMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRituximabSalvage TherapyTransplantation, AutologousConceptsB-cell depletionHD cytarabineB cellsCell lymphomaPeripheral blood stem cell mobilizationBlood stem cell mobilizationRefractory mantle cell lymphomaHigh-dose AraCRefractory follicular lymphomaHigh-dose cytarabineCombination of rituximabGranulocyte colony-stimulating factorCollection of PBSCStem cell mobilizationMantle cell lymphomaColony-stimulating factorHD chemotherapyPeripheral CD19Concurrent administrationIndolent lymphomaPeripheral bloodPatients PCRProfound depletionCell mobilizationMedian number